THX Pharma - Public Comps and Valuation Multiples

THX Pharma Overview

About THX Pharma

THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company’s therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson’s disease, THN201 for the treatment of neurocognitive disorders in Alzheimer’s disease and THN101 for neuropathic pain.

Founded

2013

HQ

Employees

Website

theranexus.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

Last FY Revenue n/a

Last FY EBITDA -$2.8M

EV

$25.7M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

THX Pharma Financials

In the same period, THX Pharma achieved -$1.8M in LTM net income.

See THX Pharma valuation multiples based on analyst estimates

THX Pharma P&L

In the most recent fiscal year, THX Pharma reported EBITDA of -$2.8M.

THX Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See THX Pharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	n/a	XXX	n/a	XXX	XXX	XXX
Gross Profit	n/a	XXX	-$3.1M	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	n/a	XXX	-$2.8M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBIT	-$2.9M	XXX	-$3.0M	XXX	XXX	XXX
EBIT Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Profit	-$1.8M	XXX	-$2.0M	XXX	XXX	XXX
Net Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	$2.5M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for THX Pharma including revenue, profitability, and margin analysis across different time periods.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	-$3.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	-$2.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$2.9M	Analyst estimates available to subscribers	-$3.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$1.8M	Analyst estimates available to subscribers	-$2.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$2.5M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for THX Pharma

This financial data table provides comprehensive performance metrics for THX Pharma, a company based in France. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

Fiscal year EBITDA was -$2.8M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for THX Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

THX Pharma Stock Performance

THX Pharma has current market cap of EUR 21.6M (or $24.9M), and EV of EUR 22.4M (or $25.7M).

Market Cap Evolution

THX Pharma Stock Data

As of November 25, 2025, THX Pharma's stock price is EUR 2 (or $2).

See THX Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$25.7M	$24.9M	XXX	XXX	XXX	XXX	$-0.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

THX Pharma Valuation Multiples

THX Pharma's trades at n/a EV/Revenue multiple, and -9.1x EV/EBITDA.

See valuation multiples for THX Pharma and 15K+ public comps

THX Pharma Financial Valuation Multiples

As of November 25, 2025, THX Pharma has market cap of $24.9M and EV of $25.7M.

Equity research analysts estimate THX Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

THX Pharma has a P/E ratio of -13.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$24.9M	XXX	$24.9M	XXX	XXX	XXX
EV (current)	$25.7M	XXX	$25.7M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-9.1x	XXX	XXX	XXX
EV/EBIT	-8.9x	XXX	-8.5x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-13.5x	XXX	-12.2x	XXX	XXX	XXX
EV/FCF	-11.8x	XXX	-6.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get THX Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

THX Pharma Margins & Growth Rates

THX Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged -$4K for the same period.

THX Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

THX Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for THX Pharma and other 15K+ public comps

THX Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	-$4K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial